Obinutuzumab

Drug Profile

Obinutuzumab

Alternative Names: 949142-50-1; Afutuzumab; GA-101; Gazyva; Gazyvaro; R-7159; RG 7195; RG-7159; RO-5072759

Latest Information Update: 07 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GLYCART Biotechnology
  • Developer Biogen Idec; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; M. D. Anderson Cancer Center; Nippon Shinyaku; OHSU Knight Cancer Institute; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II CNS cancer; Follicular lymphoma; Graft-versus-host disease; Lupus nephritis; Mantle-cell lymphoma
  • Discontinued Primary biliary cirrhosis; Renal failure

Most Recent Events

  • 27 Jul 2017 Discontinued - Phase-I for Renal failure (Late-stage disease) in USA (IV) (Roche pipeline, August 2017)
  • 21 Jul 2017 Preregistration for Non-Hodgkin's lymphoma (Combination therapy, First-line therapy) in Belgium (IV) before July 2017
  • 21 Jul 2017 Committee for Medicinal Products for Human Use (CHMP) recommends approval of obinutuzumab for Non-Hodgkin's lymphoma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top